Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Disorders01:29

Bone Disorders

8.0K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
8.0K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

3.9K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.9K
Bone Remodeling01:40

Bone Remodeling

34.4K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
34.4K
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

3.5K
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
3.5K
Role of Vitamins in Maintaining Bone Health01:25

Role of Vitamins in Maintaining Bone Health

5.1K
The growth and maintenance of bone are regulated by a combination of nutritional factors, including vitamins, such as vitamin A, B12, C, D, and K.
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
5.1K
Bone Remodeling and Repair01:31

Bone Remodeling and Repair

9.3K
9.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Promoting contraceptive use among unmarried female migrants in one factory in Shanghai: a pilot workplace intervention.

BMC health services research·2007
Same author

Apoptosis related protein 3, an ATRA-upregulated membrane protein arrests the cell cycle at G1/S phase by decreasing the expression of cyclin D1.

Biochemical and biophysical research communications·2007
Same author

Efficient one-pot synthesis of highly substituted pyridin-2(1H)-ones via the Vilsmeier-Haack reaction of 1-acetyl,1-carbamoyl cyclopropanes.

Organic letters·2007
Same author

Effects of Andrographitis Paniculata extracts on the expression of CD40 in endothelial cells.

Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban·2007
Same author

Theoretical and experimental investigations on the size of alginate microspheres prepared by dropping and spraying.

Journal of microencapsulation·2007
Same author

Beneficial effects of losartan on vascular injury induced by advanced glycosylation end products and their receptors in spontaneous hypertension rats.

Molecular and cellular biochemistry·2007
Same journal

Type I Interferonopathies: Fifteen Years On, From Concept to Therapeutic Perspectives.

Current rheumatology reports·2026
Same journal

Intensive Care Management of ANCA-associated Vasculitides: a Narrative Review.

Current rheumatology reports·2026
Same journal

The Role of Musculoskeletal Ultrasound in Psoriatic Arthritis: From Preclinical Detection to Treatment Monitoring.

Current rheumatology reports·2026
Same journal

Correction to: Is Gout and Autoinflammatory Disease?

Current rheumatology reports·2026
Same journal

Risks and Management of Glucocorticoid Therapy for Patients with Rheumatic Disease Having Surgery.

Current rheumatology reports·2026
Same journal

Perioperative Management Considerations for Patients with Systemic Lupus Erythematosus.

Current rheumatology reports·2026
See all related articles

Related Experiment Video

Updated: May 6, 2026

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
11:47

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders

Published on: June 8, 2014

11.1K

Osteopenia: debates and dilemmas.

Jie Zhang1, Sarah L Morgan, Kenneth G Saag

  • 1Department of Epidemiology, University of Alabama at Birmingham, 1665 University Blvd, Ryals 230K, Birmingham, AL, 35294, USA, jszhang@uab.edu.

Current Rheumatology Reports
|November 14, 2013
PubMed
Summary
This summary is machine-generated.

Clinicians debate using medications for primary fracture prevention in older adults with osteopenia. This review clarifies osteopenia, fracture risk assessment, and the limited evidence for drug benefits in this population.

More Related Videos

Cantilever Bending of Murine Femoral Necks
06:44

Cantilever Bending of Murine Femoral Necks

Published on: January 5, 2022

1.8K
The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
03:52

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy

Published on: February 21, 2025

1.4K

Related Experiment Videos

Last Updated: May 6, 2026

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
11:47

A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders

Published on: June 8, 2014

11.1K
Cantilever Bending of Murine Femoral Necks
06:44

Cantilever Bending of Murine Femoral Necks

Published on: January 5, 2022

1.8K
The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
03:52

The Creation of a Rat Model for Osteosarcopenia via Ovariectomy

Published on: February 21, 2025

1.4K

Area of Science:

  • Gerontology
  • Bone Health
  • Pharmacology

Background:

  • Osteopenia is common in elderly individuals, increasing fracture risk.
  • The transition from osteopenia to osteoporosis requires careful monitoring.
  • Accurate fracture risk assessment is crucial for clinical decision-making.

Purpose of the Study:

  • To review the current understanding of osteopenia in elderly populations.
  • To discuss tools for assessing fracture risk in individuals with osteopenia.
  • To evaluate the limited evidence for pharmacologic agents in primary fracture prevention for this group.

Main Methods:

  • Literature review of studies on osteopenia prevalence and progression.
  • Analysis of fracture risk assessment tools.
  • Synthesis of evidence regarding anti-osteoporotic agents for primary prevention.

Main Results:

  • Prevalence of osteopenia and its progression to osteoporosis are characterized.
  • Clinically applicable fracture risk assessment tools are discussed.
  • Evidence for the benefits and risks of pharmacologic agents in this population is very limited.

Conclusions:

  • Further research is needed to guide the use of pharmacologic agents for primary fracture prevention in elderly individuals with osteopenia.
  • Current evidence is insufficient to strongly support or refute the use of these agents.
  • Improved understanding of this population is essential for evidence-based practice.